A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of Telmisartan and S-Amlodipine(CKD-828) Versus Telmisartan Monotherapy in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy

Trial Profile

A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of Telmisartan and S-Amlodipine(CKD-828) Versus Telmisartan Monotherapy in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2016

At a glance

  • Drugs Levamlodipine/telmisartan (Primary) ; Telmisartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms CKD-828-TEL-Phase 3
  • Sponsors Chong Kun Dang
  • Most Recent Events

    • 06 Oct 2016 Primary endpoint has been met. (Mean Sitting Diastolic Blood Pressure (MSDBP))
    • 06 Oct 2016 Results published in the Clinical Therapeutics
    • 29 Sep 2016 Results presented at the 26th Scientific Meeting of the International Society of Hypertension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top